NCTD在结肠癌CME术后患者中的应用及对其免疫功能和预后的影响评估

Application of NCTD in Patients with Colon Cancer after CME and Evaluation of Its Effect on Immune Function and Prognosis

目的探讨NCTD在结肠癌CME术后患者中的应用及对其免疫功能和预后的影响评估。方法选取60例行结肠癌根治术治疗的患者,根据术后治疗方案的不同,分为研究组及对照组两组(各30例),其中研究组(采用CME手术+术后化疗+NCTD)和对照组(采用CME手术+术后化疗),比较2组患者的临床疗效。结果两组患者的半年局部复发及生存率比较均无差异(P>0.05);化疗前两组患者免疫相关指标比较无差异(P>0.05),而化疗2个周期后研究组患者的免疫相关指标均较对照组改善明显(P<0.05);化疗2个周期后,两组患者的化疗不良反应总发生率比较无显著差异(P>0.05);化疗前两组患者的生活质量相关指标比较均无差异(P>0.05),而化疗2周期后研究组患者的生活质量较对照组提高明显(P<0.05)。结论结肠癌根治术后患者辅助化疗联合口服NCTD安全有效,同时短期内可提高患者的免疫功能及生活质量,值得临床推广应用。

Objective To investigate the application of NCTD in patients with colon cancer after CME surgery and its effect on immune function and prognosis.Methods 60 patients undergoing radical resection of colon cancer were selected and divided into 2 groups(30 cases each)according to the different postoperative treatment regimens.The research group(CME surgery+postoperative chemotherapy+NCTD)and the control group(CME surgery+postoperative chemotherapy)were compared for the clinical efficacy of the 2 groups.Results There was no difference between the 2 groups(P>0.05).There was no difference in immune-related indicators between the 2 groups before chemotherapy(P>0.05),while after 2 cycles of chemotherapy,the immune-related indicators of the study group were significantly improved compared with those of the control group(P<0.05).After2 cycles of chemotherapy,there was no significant difference in the total incidence of adverse reactions to chemotherapy between the 2 groups(P>0.05).There was no difference in the quality of life indexes between the 2 groups before chemotherapy(P>0.05),while the quality of life of the study group was significantly improved after 2 cycles of chemotherapy compared with the control group(P<0.05).Conclusion Adjuvant chemotherapy combined with oral NCTD is safe and effective after radical resection of colon cancer,and can improve patients’immune function and quality of life in a short period of time.